AI Patient Education: Evaluating ChatGPT and Gemini for Pediatric Condition Materials

By João L. Carapinha

April 22, 2025

A recent peer-reviewed study examined the effectiveness of AI patient education by comparing ChatGPT and Gemini in generating educational materials for common pediatric exanthematous conditions, including varicella, hand, foot, and mouth disease (HFMD), and measles. The findings indicated that ChatGPT produced significantly longer responses than Gemini (p=0.047). However, readability, ease of understanding, and reliability—measured by Flesch-Kincaid and a modified DISCERN score—showed no significant difference between the two AI tools.

Depth and Clarity: A Balancing Act

  • Content Depth vs. Readability: ChatGPT generated higher word counts, potentially offering in-depth information. Yet, this did not improve readability or reliability compared to Gemini. Both AI tools provided materials close to a ninth-grade reading level, which may challenge certain patient populations.
  • Reliability and Quality: Gemini achieved a slightly higher mean reliability score (3/5 vs. 2.67/5 for ChatGPT), though this difference was not statistically significant. Both scores indicate room for improvement in the quality of AI Patient Education materials.
  • No Correlation Between Readability and Reliability: The study found no link between ease of reading and reliability. Simpler text does not necessarily mean higher quality or more accurate information.

Importance of Accessible Patient Education

Varicella, HFMD, and measles are frequent viral exanthems in pediatrics. Early recognition and parental understanding are critical for quality management and minimizing disease transmission. Health organizations like WHO and CDC stress the need for clear, accurate, and comprehensible patient education materials in pediatric infectious diseases.

Large language models like ChatGPT and Gemini are increasingly used for patient education. However, these tools need thorough evaluation for accuracy, readability, and appropriateness across diverse patient demographics. Most guidelines recommend patient materials at a 6th to 8th-grade reading level—a benchmark neither AI tool consistently met in this study.

Implications for Healthcare and Economic Outcomes

Reading level difficulties present barriers to equitable healthcare outcomes. Low health literacy is linked to increased healthcare costs, poorer outcomes, and diminished patient engagement—key concerns for payers and providers. As AI-generated content grows in digital health, payers may demand validation of accuracy, readability, and patient-centered design for reimbursement. This study highlights the need for continuous AI validation, expert oversight, and iterative improvements before broad clinical or commercial use.

The authors suggest real-time validation, clinician review, and structured patient feedback could improve content quality. Such enhancements may be prerequisites for payer support and integration into healthcare systems.

Findings and Future Directions

In summary, this study shows AI tools like ChatGPT and Gemini can generate educational materials on pediatric rashes, but current outputs fall short of optimal readability and reliability standards. This underscores the need for real-world validation, multidisciplinary oversight, and adherence to health communication guidelines to fully leverage AI patient education—impacting public health, cost-effectiveness, and healthcare access.

Reference url

Recent Posts

access to medicines
         

Quantifying EU Medicine Access Challenges

🔍 Are we creating a healthcare system that truly works for everyone?

Recent findings from EFPIA shed light on alarming inequities in access to medicines across Europe, showing that only 46% of approved drugs are available to patients this year. With significant delays affecting smaller markets and critical cancer treatments, this article explores the systemic barriers at play and innovative solutions proposed to ensure fair access.

Dive into the full article to uncover how we can collectively shape a more equitable healthcare landscape.

#SyenzaNews #healthcare #MarketAccess

UK Medicine Payment Rates
      

Revitalizing Innovation: The Impact of UK Medicine Payment Rates

💡 Are the UK’s medicine payment rates stifling innovation in life sciences?

Recent analysis reveals that the staggering 23.5% payment rate for pharmaceuticals is not just limiting NHS spending but also curtailing R&D investments, delaying new drug launches, and threatening workforce stability. If we can lower these rates to below 10%, we could unleash significant growth and restore the UK’s competitive edge in the global life sciences landscape.

Discover the critical insights and recommendations that could reshape the future of healthcare in the UK.

#SyenzaNews #healthcarepolicy #innovation

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.